Comments
Piramal Imaging, part of Piramal Enterprises Ltd, has entered into an exclusive licensing agreement with South Korea’s Ci-Co Healthcare, which will facilitate getting approvals from Korean health authorities for the Indian company’s imaging agent, florbetaben F18.
Seoul-based Ci-Co will obtain market authorisation from the Korean health authorities and commercialise the PET amyloid imaging agent, florbetaben F18, in South Korea, a Piramal note said. Ci-Co has further assigned the manufacturing and supply of florbetaben F18 with DuChemBio, a market leading radiopharmacy network in Korea. Nearly one in every 10 or 541,000 senior citizens in Korea suffer from Alzheimer’s disease (where the individual’s memory deteriorates). This number was up over 8 percent in 2010, and if the trend continues it is expected to exceed one million in 2024, it added.
Florbetaben F18 is an investigational PET amyloid imaging agent that is still under review by the US Food and Drug Administration and the European Medicines Agency, the company added.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.